-
1
-
-
0018939225
-
Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol lowering agent
-
1. Alberts AW, Chen J, Kuron G, Hunt V, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Hensens O, Hirshfield J, Hoogstee K, Liesch J and Springer J, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol lowering agent. Proc Nad Acad Sci USA 77: 3957-3961, 1980.
-
(1980)
Proc Nad Acad Sci USA
, vol.77
, pp. 3957-3961
-
-
Alberts, A.W.1
Chen, J.2
Kuron, G.3
Hunt, V.4
Hoffman, C.5
Rothrock, J.6
Lopez, M.7
Joshua, H.8
Harris, E.9
Patchett, A.10
Hensens, O.11
Hirshfield, J.12
Hoogstee, K.13
Liesch, J.14
Springer, J.15
-
2
-
-
0022486908
-
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: 4. Side-chain ester derivatives of mevinolin
-
2. Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL and Willard AK, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: 4. side-chain ester derivatives of mevinolin. J Med Chem 29: 849-852, 1986.
-
(1986)
J Med Chem
, vol.29
, pp. 849-852
-
-
Hoffman, W.F.1
Alberts, A.W.2
Anderson, P.S.3
Chen, J.S.4
Smith, R.L.5
Willard, A.K.6
-
3
-
-
0022485201
-
CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of steroid synthesis and hypolipidemic effects on various animal species
-
3. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y and Fujii S, CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of steroid synthesis and hypolipidemic effects on various animal species. Biochem Biophys Acta 877: 50-60, 1986.
-
(1986)
Biochem Biophys Acta
, vol.877
, pp. 50-60
-
-
Tsujita, Y.1
Kuroda, M.2
Shimada, Y.3
Tanzawa, K.4
Arai, M.5
Kaneko, I.6
Tanaka, M.7
Masuda, H.8
Tarumi, C.9
Watanabe, Y.10
Fujii, S.11
-
4
-
-
0025944198
-
Relative lipophylicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
-
4. Serajuddin ATM, Ranadive SA and Mahoney EM, Relative lipophylicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharmacol Sci 80: 830-834, 1991.
-
(1991)
J Pharmacol Sci
, vol.80
, pp. 830-834
-
-
Serajuddin, A.T.M.1
Ranadive, S.A.2
Mahoney, E.M.3
-
5
-
-
0002320371
-
Hydrophilicity and the differential pharmacology of pravastatin. Lipid management: Pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors
-
5. Scott WA, Hydrophilicity and the differential pharmacology of pravastatin. Lipid management: Pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. Round table ser 16: 17-25, 1990.
-
(1990)
Round Table Ser
, vol.16
, pp. 17-25
-
-
Scott, W.A.1
-
6
-
-
0024461808
-
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens
-
6. Mosley ST, Kalinowski SS, Shafer BL and Tanaka RD, Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 30: 1411-1420, 1989.
-
(1989)
J Lipid Res
, vol.30
, pp. 1411-1420
-
-
Mosley, S.T.1
Kalinowski, S.S.2
Shafer, B.L.3
Tanaka, R.D.4
-
7
-
-
0025286202
-
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
-
7. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K and Yamazaki M, Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045: 115-120, 1990.
-
(1990)
Biochim Biophys Acta
, vol.1045
, pp. 115-120
-
-
Koga, T.1
Shimada, Y.2
Kuroda, M.3
Tsujita, Y.4
Hasegawa, K.5
Yamazaki, M.6
-
8
-
-
0026641368
-
Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de now sterol synthesis and active drug concentrations in the liver, spleen and testis in rat
-
8. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H and Tsujita Y, Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de now sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209: 315-319, 1992.
-
(1992)
Eur J Biochem
, vol.209
, pp. 315-319
-
-
Koga, T.1
Fukuda, K.2
Shimada, Y.3
Fukami, M.4
Koike, H.5
Tsujita, Y.6
-
9
-
-
0027401883
-
Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens
-
9. De Vries ACJ, Vermeer A, Bloemendal H and Cohen LH, Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthamol Vis Sci 34: 377-384, 1993.
-
(1993)
Invest Ophthamol Vis Sci
, vol.34
, pp. 377-384
-
-
De Vries, A.C.J.1
Vermeer, A.2
Bloemendal, H.3
Cohen, L.H.4
-
10
-
-
0028814860
-
Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types
-
10. Van Vliet AK, Van Thiel GCF, Huisman RH, Moshage H, Yap SH and Cohen LH, Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1254: 105-111, 1995.
-
(1995)
Biochim Biophys Acta
, vol.1254
, pp. 105-111
-
-
Van Vliet, A.K.1
Van Thiel, G.C.F.2
Huisman, R.H.3
Moshage, H.4
Yap, S.H.5
Cohen, L.H.6
-
11
-
-
0026591167
-
Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture
-
11. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C and Horiuchi S, Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43: 667-670, 1992.
-
(1992)
Biochem Pharmacol
, vol.43
, pp. 667-670
-
-
Komai, T.1
Shigehara, E.2
Tokui, T.3
Koga, T.4
Ishigami, M.5
Kuroiwa, C.6
Horiuchi, S.7
-
13
-
-
0026778180
-
Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter
-
13. Ziegler K and Stünkel W, Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1139: 203-209, 1992.
-
(1992)
Biochim Biophys Acta
, vol.1139
, pp. 203-209
-
-
Ziegler, K.1
Stünkel, W.2
-
14
-
-
0025120211
-
Regulation of mevalonate pathway
-
14-Goldstein JL and Brown MS, Regulation of mevalonate pathway. Nature 343: 425-430, 1990.
-
(1990)
Nature
, vol.343
, pp. 425-430
-
-
Goldstein, J.L.1
Brown, M.S.2
-
15
-
-
0025649688
-
Posttranslational modification of proteins by isoprenoids in mammalian cells
-
15. Maltese WA, Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328, 1990.
-
(1990)
FASEB J
, vol.4
, pp. 3319-3328
-
-
Maltese, W.A.1
-
16
-
-
0026895892
-
Protein prenylation: Key to ras function and cancer intervention?
-
16. Khosravi-Far R, Cox AD, Kato K and Der CJ, Protein prenylation: key to ras function and cancer intervention? Cell Growth Diff 3: 461-469, 1992.
-
(1992)
Cell Growth Diff
, vol.3
, pp. 461-469
-
-
Khosravi-Far, R.1
Cox, A.D.2
Kato, K.3
Der, C.J.4
-
18
-
-
0028099592
-
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis
-
18. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J and Sever P, Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772, 1994.
-
(1994)
Eur J Clin Invest
, vol.24
, pp. 766-772
-
-
Munro, E.1
Patel, M.2
Chan, P.3
Betteridge, L.4
Clunn, G.5
Gallagher, K.6
Hughes, A.7
Schachter, M.8
Wolfe, J.9
Sever, P.10
-
19
-
-
0027185879
-
Relationship between mevalonate pathway and arterial myocyte proliferations: In vitro studies with inhibitors of HMG-CoA reductase
-
19. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R and Paoletti R, Relationship between mevalonate pathway and arterial myocyte proliferations: in vitro studies with inhibitors of HMG-CoA reductase, Atherosclerosis 101: 117-125, 1993.
-
(1993)
Atherosclerosis
, vol.101
, pp. 117-125
-
-
Corsini, A.1
Mazzotti, M.2
Raiteri, M.3
Soma, M.R.4
Gabbiani, G.5
Fumagalli, R.6
Paoletti, R.7
-
20
-
-
0024504543
-
Effect of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro
-
20. Falke P, Mattiasson I, Stavenow L and Hood B, Effect of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 64: 173-176, 1989.
-
(1989)
Pharmacol Toxicol
, vol.64
, pp. 173-176
-
-
Falke, P.1
Mattiasson, I.2
Stavenow, L.3
Hood, B.4
-
21
-
-
0023697436
-
Efficacy and long-term adverse effect pattern of lovastatin
-
21. Tobert JA, Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 28J-34J, 1988.
-
(1988)
Am J Cardiol
, vol.62
-
-
Tobert, J.A.1
-
22
-
-
0024445005
-
Plasma mevalonate response in lovastatin-related myopathy
-
22. Maher VMG, Pappu A, Illingworth DR and Thompson GR, Plasma mevalonate response in lovastatin-related myopathy. Lancet 4: 1098, 1989.
-
(1989)
Lancet
, vol.4
, pp. 1098
-
-
Maher, V.M.G.1
Pappu, A.2
Illingworth, D.R.3
Thompson, G.R.4
-
24
-
-
0023860312
-
Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
-
24. East C, Alivizatos PA, Grundy SM, Jones PH and Farmer JA, Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318: 47-48, 1988.
-
(1988)
N Engl J Med
, vol.318
, pp. 47-48
-
-
East, C.1
Alivizatos, P.A.2
Grundy, S.M.3
Jones, P.H.4
Farmer, J.A.5
-
25
-
-
0024433626
-
Lovastatin, isoprenes, and myopathy
-
25. Walravens PA, Greene C and Frefman FE, Lovastatin, isoprenes, and myopathy. Lancet 2: 1097-1098, 1989.
-
(1989)
Lancet
, vol.2
, pp. 1097-1098
-
-
Walravens, P.A.1
Greene, C.2
Frefman, F.E.3
-
26
-
-
0026502596
-
Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria
-
26. Chan PC, Robinson JD, Yeung WC, Cheng K, Yeung HW and Tsang MT, Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7: 93-99, 1992.
-
(1992)
Nephrol Dial Transplant
, vol.7
, pp. 93-99
-
-
Chan, P.C.1
Robinson, J.D.2
Yeung, W.C.3
Cheng, K.4
Yeung, H.W.5
Tsang, M.T.6
-
27
-
-
0025613424
-
Rhabdomyolysis secondary to lovastatin therapy
-
27. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C and Scottolini AG, Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 36: 2145-2147, 1990.
-
(1990)
Clin Chem
, vol.36
, pp. 2145-2147
-
-
Manoukian, A.A.1
Bhagavan, N.V.2
Hayashi, T.3
Nestor, T.A.4
Rios, C.5
Scottolini, A.G.6
-
28
-
-
0025037123
-
Muscle side effects associated with simvastatin therapy
-
28. England JDF, Viles A, Walsh JC and Stewart PM, Muscle side effects associated with simvastatin therapy. Med J Austral 153: 562-563, 1990.
-
(1990)
Med J Austral
, vol.153
, pp. 562-563
-
-
England, J.D.F.1
Viles, A.2
Walsh, J.C.3
Stewart, P.M.4
-
30
-
-
0026672714
-
Massive rhabdomyolysis and simvastatin
-
30. Bizzaro N, Bagolin E, Milani L, Cereser C and Finco B, Massive rhabdomyolysis and simvastatin. Clin Chem 38: 1504, 1992.
-
(1992)
Clin Chem
, vol.38
, pp. 1504
-
-
Bizzaro, N.1
Bagolin, E.2
Milani, L.3
Cereser, C.4
Finco, B.5
-
31
-
-
0026032967
-
Rhabdomyolysis with simvastatin use
-
31. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R and Musso JL, Rhabdomyolysis with simvastatin use. Nephron 57: 365-366, 1991.
-
(1991)
Nephron
, vol.57
, pp. 365-366
-
-
Berland, Y.1
Vacher Coponat, H.2
Durand, C.3
Baz, M.4
Laugier, R.5
Musso, J.L.6
-
32
-
-
0026722199
-
Pravastatin-associated inflammatory myopathy
-
32. Schalke BB, Schmidt B, Toyka K and Hartung H, Pravastatin-associated inflammatory myopathy. New Engl J Med 327: 649-650, 1992.
-
(1992)
New Engl J Med
, vol.327
, pp. 649-650
-
-
Schalke, B.B.1
Schmidt, B.2
Toyka, K.3
Hartung, H.4
-
33
-
-
8244228798
-
Rhabdomyolysis related to ingestion of pravastatin
-
33. Perault MC, Ladouch-Bures L, Dejean C, Delaunay C, Pouget Abadie JF and Vandel B, Rhabdomyolysis related to ingestion of pravastatin. Therapie 48: 487, 1993.
-
(1993)
Therapie
, vol.48
, pp. 487
-
-
Perault, M.C.1
Ladouch-Bures, L.2
Dejean, C.3
Delaunay, C.4
Pouget Abadie, J.F.5
Vandel, B.6
-
34
-
-
0027291548
-
Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase
-
34. Decoulx E, Millaire A, De Groote P, Mahieux G and Ducloux G, Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase. Ann Cardiol Angeiol 42: 267-269, 1993.
-
(1993)
Ann Cardiol Angeiol
, vol.42
, pp. 267-269
-
-
Decoulx, E.1
Millaire, A.2
De Groote, P.3
Mahieux, G.4
Ducloux, G.5
-
35
-
-
0026018161
-
Cholesterol-lowering agent myopathy (CLAM)
-
35. London SF, Gross KF and Riegel SP, Cholesterol-lowering agent myopathy (CLAM). Neurology 41: 1159-1160, 1991.
-
(1991)
Neurology
, vol.41
, pp. 1159-1160
-
-
London, S.F.1
Gross, K.F.2
Riegel, S.P.3
-
36
-
-
0027772590
-
Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts
-
36. Belo RS, Jamieson JC and Wright JA, Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts. Mol Cell Biochem 126: 159-167, 1993.
-
(1993)
Mol Cell Biochem
, vol.126
, pp. 159-167
-
-
Belo, R.S.1
Jamieson, J.C.2
Wright, J.A.3
-
37
-
-
0028962803
-
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyrne A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
-
37. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D and Durham SK, In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyrne A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131: 163-174, 1995.
-
(1995)
Toxicol Appl Pharmacol
, vol.131
, pp. 163-174
-
-
Masters, B.A.1
Palmoski, M.J.2
Flint, O.P.3
Gregg, R.E.4
Wang-Iverson, D.5
Durham, S.K.6
-
38
-
-
0015903694
-
The regeneration of skeletal muscle - A review
-
38. Carlson BM, The regeneration of skeletal muscle - a review. Am J Anat 137: 119-150, 1973.
-
(1973)
Am J Anat
, vol.137
, pp. 119-150
-
-
Carlson, B.M.1
-
39
-
-
0017714563
-
A quantitative technique for growing human adult muscle in culture starting from mononucleated cells
-
39. Yasin R, van Beers G, Nurse KCE, Al-Ani S, Landon DN and Thompson EJ, A quantitative technique for growing human adult muscle in culture starting from mononucleated cells. J Neurol Sci 32: 347-360, 1977.
-
(1977)
J Neurol Sci
, vol.32
, pp. 347-360
-
-
Yasin, R.1
Van Beers, G.2
Nurse, K.C.E.3
Al-Ani, S.4
Landon, D.N.5
Thompson, E.J.6
-
40
-
-
71849104860
-
Protein measurements with the folin reagent
-
40. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurements with the folin reagent. J Biol Chem 193: 265-275, 1951.
-
(1951)
J Biol Chem
, vol.193
, pp. 265-275
-
-
Lowry, O.H.1
Rosebrough, N.J.2
Farr, A.L.3
Randall, R.J.4
-
41
-
-
0023121807
-
Regulation of 3-hydroxy-3-methylglutaryl coenzyrne A reductase in human hepatoma cell line HepG2; effects of inhibitors of cholesterol synthesis on enzyme activity
-
41. Boogaard A, Griffioen M and Cohen LH, Regulation of 3-hydroxy-3-methylglutaryl coenzyrne A reductase in human hepatoma cell line HepG2; effects of inhibitors of cholesterol synthesis on enzyme activity. Biochem J 241: 345-351, 1987.
-
(1987)
Biochem J
, vol.241
, pp. 345-351
-
-
Boogaard, A.1
Griffioen, M.2
Cohen, L.H.3
-
42
-
-
0024595042
-
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill
-
42. Bagge Hansen M, Nielsen SE and Berg K, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
-
(1989)
J Immunol Methods
, vol.119
, pp. 203-210
-
-
Bagge Hansen, M.1
Nielsen, S.E.2
Berg, K.3
-
43
-
-
0000387894
-
Adenosin-5′-triphosphat -Bestimmung mit hexokinase und glucose-6-phosphate dehydrogenase
-
Ed. Bergmeyer HU, Verlag Chemie, Weinheim, Germany
-
43. Lamprecht W and Trantschold I, Adenosin-5′-triphosphat -Bestimmung mit hexokinase und glucose-6-phosphate dehydrogenase. In: Methoden der Enzymatischen Analyse (Ed. Bergmeyer HU), pp. 2024-2033. Verlag Chemie, Weinheim, Germany, 1970.
-
(1970)
Methoden der Enzymatischen Analyse
, pp. 2024-2033
-
-
Lamprecht, W.1
Trantschold, I.2
-
44
-
-
0019135838
-
Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth
-
44-Brown MS and Goldstein JL, Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21: 505-517, 1980.
-
(1980)
J Lipid Res
, vol.21
, pp. 505-517
-
-
Brown, M.S.1
Goldstein, J.L.2
-
45
-
-
0025202968
-
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis
-
45. Sinensky M, Beck LA, Leonard S and Evans R, Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265: 19937-19941, 1990.
-
(1990)
J Biol Chem
, vol.265
, pp. 19937-19941
-
-
Sinensky, M.1
Beck, L.A.2
Leonard, S.3
Evans, R.4
-
46
-
-
0024998547
-
Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells
-
46. Nagata Y, Hidaka Y, Ishida F and Kamei T, Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Biochem Pharmacol 40: 843-850, 1990.
-
(1990)
Biochem Pharmacol
, vol.40
, pp. 843-850
-
-
Nagata, Y.1
Hidaka, Y.2
Ishida, F.3
Kamei, T.4
-
47
-
-
0026814425
-
Comparative pharmokinetics of lovastatin, simvastatin and pravastatin in humans
-
47. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F and Rogers JD, Comparative pharmokinetics of lovastatin, simvastatin and pravastatin in humans. J Cli Pharmacol 32: 136-140, 1992.
-
(1992)
J Cli Pharmacol
, vol.32
, pp. 136-140
-
-
Pentikainen, P.J.1
Saraheimo, M.2
Schwartz, J.I.3
Amin, R.D.4
Schwartz, M.S.5
Brunner-Ferber, F.6
Rogers, J.D.7
|